Dan O'Day, Gilead CEO (Getty Images)

Covid-19 roundup: Mod­er­na posts $1.1B in Covid-19 vac­cine de­posits; Gilead CEO sees po­ten­tial need for Vek­lury on a 'sea­son­al ba­sis'

Mod­er­na’s $MR­NA ex­ec­u­tive team is clear­ly itch­ing to get a near-term EUA for their Covid-19 vac­cine.

The mR­NA wun­derkind post­ed an up­date on their piv­otal tri­al for mR­NA-1273, with a note that they have $1.1 bil­lion in cus­tomer de­posits for the vac­cine.

Right now Mod­er­na CEO Stéphane Ban­cel and his team are neck-and-neck with Pfiz­er/BioN­Tech in a race to un­veil da­ta on what could be the first vac­cines for the pan­dem­ic. And he is not one to down­play the com­pa­ny’s prospects.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.